Author + information
- Received July 27, 2006
- Revision received December 6, 2006
- Accepted December 10, 2006
- Published online April 10, 2007.
- Mauro Maioli, MD⁎ (, )
- Francesco Bellandi, MD,
- Mario Leoncini, MD,
- Anna Toso, MD and
- Roberto Piero Dabizzi, MD
- ↵⁎Reprint requests and correspondence:
Dr. Mauro Maioli, Via degli Arcipressi 3, 50143, Florence, Italy.
Objectives This prospective randomized trial evaluates the impact of early abciximab administration on angiographic and left ventricular function parameters.
Background Glycoprotein IIb/IIIa inhibitors improve myocardial reperfusion in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI), but optimal timing of administration remains unclear.
Methods Two-hundred ten consecutive patients with first AMI undergoing primary PCI were randomized to abciximab administration either in the emergency room (early group: 105 patients) or in the catheterization laboratory, after coronary angiography (late group: 105 patients). Primary end points were initial Thrombolysis In Myocardial Infarction (TIMI) flow grade, corrected TIMI frame count (cTFC), and myocardial blush grade (MBG), as well as left ventricular function recovery as assessed by serial echocardiographic evaluations.
Results Angiographic pre-PCI analysis showed a significantly better initial TIMI flow grade 3 (24% vs. 10%; p = 0.01), cTFC (78 ± 30 frames vs. 92 ± 21 frames; p = 0.001), and MBG 2 or 3 (15% vs. 6%; p = 0.02) favoring the early group. Consistently, post-PCI tissue perfusion parameters were significantly improved in the early group, as assessed by 60-min ST-segment reduction ≥70% (50% vs. 35%; p = 0.03) and MBG 2 or 3 (79% vs. 58%; p = 0.001). Left ventricular function recovery at 1 month was significantly greater in the early group (mean gain ejection fraction 8 ± 7% vs. 6 ± 7%, p = 0.02; mean gain wall motion score index 0.4 ± 0.3 vs. 0.3 ± 0.3, p = 0.03).
Conclusions In patients with AMI treated with primary PCI, early abciximab administration improves pre-PCI angiographic findings, post-PCI tissue perfusion, and 1-month left ventricular function recovery, possibly by starting early recanalization of the infarct-related artery.
- Received July 27, 2006.
- Revision received December 6, 2006.
- Accepted December 10, 2006.
- American College of Cardiology Foundation